Cue Biopharma Inc. (CUE) and Synthetic Biologics Inc. (NYSEAMERICAN:SYN) Comparing side by side

Both Cue Biopharma Inc. (NASDAQ:CUE) and Synthetic Biologics Inc. (NYSEAMERICAN:SYN) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cue Biopharma Inc. N/A 152.94 37.80M -1.99 0.00
Synthetic Biologics Inc. N/A 0.00 7.59M 3.89 0.18

Table 1 demonstrates Cue Biopharma Inc. and Synthetic Biologics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows us Cue Biopharma Inc. and Synthetic Biologics Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Cue Biopharma Inc. 0.00% -67.9% -62.3%
Synthetic Biologics Inc. 0.00% 203.6% -60.1%

Liquidity

Cue Biopharma Inc.’s Current Ratio is 7.8 while its Quick Ratio is 7.8. On the competitive side is, Synthetic Biologics Inc. which has a 2.6 Current Ratio and a 2.6 Quick Ratio. Cue Biopharma Inc. is better positioned to pay off short and long-term obligations compared to Synthetic Biologics Inc.

Institutional and Insider Ownership

Cue Biopharma Inc. and Synthetic Biologics Inc. has shares held by institutional investors as follows: 23% and 6.6%. 3.6% are Cue Biopharma Inc.’s share held by insiders. Insiders Comparatively, held 0.11% of Synthetic Biologics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cue Biopharma Inc. 4.49% -32.74% -47.92% -66.23% 0% -57.95%
Synthetic Biologics Inc. -7.93% -21.37% -74.08% -91.3% -96.7% -96.06%

For the past year Cue Biopharma Inc. was less bearish than Synthetic Biologics Inc.

Summary

Synthetic Biologics Inc. beats Cue Biopharma Inc. on 5 of the 8 factors.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.